Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol

Approximately 80% to 90% of patients with low-risk rhabdomyosarcoma can be cured. However, cured patients often face long-term complications associated with the treatment. An important factor in the treatment plan is the dose of cyclophosphamide administered because the dose can have both acute and...

Full description

Saved in:

Bibliographic Details
Published in:	Medicine (Baltimore) Vol. 98; no. 52; p. e18344
Main Authors:	Miyachi, Mitsuru, Tsuchiya, Kunihiko, Hosono, Ako, Ogawa, Atsushi, Koh, Katsuyoshi, Kikuta, Atsushi, Hara, Junichi, Teramukai, Satoshi, Hosoi, Hajime
Format:	Journal Article
Language:	English
Published:	United States the Author(s). Published by Wolters Kluwer Health, Inc 01.12.2019 Wolters Kluwer Health
Subjects:	Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Protocols Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use Dactinomycin - administration & dosage Dactinomycin - therapeutic use Humans Irinotecan - administration & dosage Irinotecan - therapeutic use Neoplasm Staging Rhabdomyosarcoma - drug therapy Rhabdomyosarcoma - pathology Study Protocol Clinical Trial Treatment Outcome Vincristine - administration & dosage Vincristine - therapeutic use
ISSN:	0025-7974, 1536-5964, 1536-5964
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!